{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:46:41Z","timestamp":1773845201786,"version":"3.50.1"},"reference-count":29,"publisher":"Royal College of General Practitioners","issue":"740","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Gen Pract"],"accepted":{"date-parts":[[2023,7,20]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Studies utilising genotyping methods report the prevalence of familial hypercholesterolaemia to be as high as one in 137 of the adult population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To estimate the prevalence of familial hypercholesterolaemia measured by clinically coded diagnosis, associated treatments, and lipid measurements observed in UK primary care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design and setting<\/jats:title><jats:p>This was a retrospective analysis using the Clinical Practice Research Datalink (CPRD) GOLD database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Patients aged \u226518 years and actively registered on the index date (30 June 2018) formed the study cohort. Point prevalence of familial hypercholesterolaemia for 2018 was estimated overall and for each nation of the UK. Patients with familial hypercholesterolaemia were stratified into primary and secondary prevention groups, defined as those with\/without a prior diagnosis of atherosclerotic cardiovascular disease. Prevalence estimates and extrapolations were replicated for these subgroups. Baseline demographic, lipid, and clinical characteristics for the prevalent cohort were presented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 4048 patients with familial hypercholesterolaemia formed the study cohort. The estimated familial hypercholesterolaemia prevalence for the UK was 16.4 per 10 000 (95% confidence interval [CI] = 16.0 to 16.9). Of these, 2646 (65.4%) patients with familial hypercholesterolaemia had a recent prescription for lipid-lowering therapy. Mean lipid levels were lower for those treated with lipid-lowering therapy compared with those untreated: 5.34 mmol\/L (SD 1.50) versus 6.25 mmol\/L (SD 1.55) for total cholesterol and 3.15 mmol\/L (SD 1.34) versus 3.96 mmol\/L (SD 1.36) for low-level density lipoprotein cholesterol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The estimated prevalence of familial hypercholesterolaemia was one in 608 of the population, less than expected from other studies, which may indicate that familial hypercholesterolaemia is under-recognised in UK primary care. Over one-third of diagnosed patients were undertreated and many did not achieve target goals, placing them at risk of cardiovascular events.<\/jats:p><\/jats:sec>","DOI":"10.3399\/bjgp.2023.0010","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T16:10:17Z","timestamp":1690992617000},"page":"e174-e182","source":"Crossref","is-referenced-by-count":3,"title":["Familial hypercholesterolaemia in UK primary care: a Clinical Practice Research Datalink study of an under-recognised condition"],"prefix":"10.3399","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9581-1102","authenticated-orcid":false,"given":"Adeline","family":"Durand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8796-7406","authenticated-orcid":false,"given":"Christopher Ll","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Tinsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9688-6031","authenticated-orcid":false,"given":"Terry","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0421-7392","authenticated-orcid":false,"given":"Charlotte L","family":"Bitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7968-7073","authenticated-orcid":false,"given":"Raquel","family":"Lahoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1987","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"2024082303500707000_74.740.e174.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.05.044"},{"key":"2024082303500707000_74.740.e174.2","unstructured":"National Institute for Health and Care Excellence (2008) Familial hypercholesterolaemia: identification and management. Clinical guideline CG71 (NICE, London) https:\/\/www.nice.org.uk\/guidance\/CG71 (accessed 11 Aug 2023)."},{"key":"2024082303500707000_74.740.e174.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.303.6794.89"},{"key":"2024082303500707000_74.740.e174.4","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-822987"},{"key":"2024082303500707000_74.740.e174.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(02)00330-1"},{"key":"2024082303500707000_74.740.e174.6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044795"},{"key":"2024082303500707000_74.740.e174.7","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh236"},{"key":"2024082303500707000_74.740.e174.8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.atherosclerosis.2014.05.755","article-title":"UK consensus position on the management of homozygous familial hypercholesterolaemia and the introduction of new agents (2014)","volume":"235","author":"Cramb","year":"2014","journal-title":"Atherosclerosis"},{"key":"2024082303500707000_74.740.e174.9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1563"},{"key":"2024082303500707000_74.740.e174.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht273"},{"key":"2024082303500707000_74.740.e174.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(98)00200-7"},{"key":"2024082303500707000_74.740.e174.12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv289"},{"key":"2024082303500707000_74.740.e174.13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(21)01122-3","article-title":"Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"2024082303500707000_74.740.e174.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a2423"},{"key":"2024082303500707000_74.740.e174.15","unstructured":"Royal College of Physicians (2015) The national audit of the management of familial hypercholesterolaemia 2010, https:\/\/www.rcplondon.ac.uk\/projects\/outputs\/familial-hypercholesterolaemia-audit (accessed 11 Aug 2023)."},{"key":"2024082303500707000_74.740.e174.16","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2024082303500707000_74.740.e174.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020738"},{"key":"2024082303500707000_74.740.e174.18","doi-asserted-by":"publisher","DOI":"10.14236\/jhi.v19i3.811"},{"key":"2024082303500707000_74.740.e174.19","unstructured":"Office for National Statistics (2019) Population estimates for the UK, England and Wales, Scotland and Northern Ireland, https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/bulletins\/annualmidyearpopulationestimates\/mid2018 (accessed 11 Aug 2023)."},{"key":"2024082303500707000_74.740.e174.20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.699579"},{"key":"2024082303500707000_74.740.e174.21","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"key":"2024082303500707000_74.740.e174.22","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437741.48606.98"},{"key":"2024082303500707000_74.740.e174.23","unstructured":"National Institute for Health and Care Excellence (2014) Cardiovascular disease: risk assessment and reduction, including lipid modification CG181 (NICE, London) www.nice.org.uk\/guidance\/cg181 (accessed 11 Aug 2023)."},{"key":"2024082303500707000_74.740.e174.24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2019.05.017","article-title":"Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: a cohort study","volume":"287","author":"Iyen","year":"2019","journal-title":"Atherosclerosis"},{"key":"2024082303500707000_74.740.e174.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04053-8"},{"key":"2024082303500707000_74.740.e174.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800742"},{"key":"2024082303500707000_74.740.e174.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032321"},{"key":"2024082303500707000_74.740.e174.28","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011246"},{"key":"2024082303500707000_74.740.e174.29","unstructured":"National Institute for Health and Care Excellence (2016) Ezetimibe for treating primary heterozygous familial and non-familial hypercholesterolaemia TA385 (NICE, London) https:\/\/www.nice.org.uk\/guidance\/TA385 (accessed 11 Aug 2023)."}],"container-title":["British Journal of General Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3399\/BJGP.2023.0010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:51:19Z","timestamp":1724410279000},"score":1,"resource":{"primary":{"URL":"http:\/\/bjgp.org\/lookup\/doi\/10.3399\/BJGP.2023.0010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":29,"journal-issue":{"issue":"740","published-online":{"date-parts":[[2024,2,29]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.3399\/BJGP.2023.0010"],"URL":"https:\/\/doi.org\/10.3399\/bjgp.2023.0010","relation":{},"ISSN":["0960-1643","1478-5242"],"issn-type":[{"value":"0960-1643","type":"print"},{"value":"1478-5242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]}}}